Overview

Gender

male

Investor Type

Investment Partner

Garheng joined Sofinnova Ventures in 2010 as a General Partner to focus on life science investments. He has served as chairman and director on the boards of numerous companies, and operated as interim CEO for two venture-backed companies. For the previous 10 years, he was at Intersouth Partners, most recently as a general partner. During this time he served as the founding investor and chairman of Cellective Therapeutics (acquired by AstraZeneca), Chairman of Serenex (acquired by Pfizer), Chairman of Novamin Technologies (acquired by GlaxoSmithKline), and lead investor of the first financing for Alimera Sciences (Nasdaq: ALIM). He has also led or been significantly involved in the investments of Cempra Pharmaceuticals (Nasdaq: CEMP, Chairman), Viamet Pharmaceuticals (Chairman), Proteon Therapeutics, Applied Genetic Technology Corporation, TransEnterix, Calibra Medical (Acquired by J&J), CancerGuide Diagnostics, Aldagen (Acquired by Cytomedix) and nContact Surgical. Garheng most recently led Sofinnova\'s investment in Alimera Sciences, Histogenics (Chairman), Salveo Specialty Pharmacy and SARcode Bioscience (acquired by Shire).

Garheng serves or has served on the boards of directors of the SEBIO organization, the North Carolina Biotechnology Center, the Duke University Medical Center Board of Visitors, the Council for Entrepreneurial Development (CED), the Hamner Institutes for Life Sciences, the North Carolina Medical Device Organization, the University of Florida Biotechnology Council, the University of Virginia Ivy Foundation, the Pennsylvania Life Sciences Greenhouse, the Southeast Universities Research Association, the Investor Advisory Board for the Florida Institute for the Commercialization of Public Research, and the Corporate Chaplains of America. He has also served on the Duke Medical Center Institutional Review Board (IRB) and as faculty at the Duke Fuqua School of Business as a Senior Scholar.